The reiteration of an Outperform rating by Baird analyst Colleen Kusy indicates a positive outlook for Ocular Therapeutix. The maintained price target of $18 also suggests that the analyst believes the stock is undervalued at current levels. This could potentially lead to an increase in the stock's price in the short term.